期刊
CANCER LETTERS
卷 342, 期 2, 页码 170-177出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.01.020
关键词
Epigenetics; Biomarker; Methylation; MicroRNA; Melanoma; Prognosis
类别
资金
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Melanoma Research Alliance
- National Institutes of Health, National Cancer Institute [P01 CA012582, P01 CA029605]
Epigenetic aberrations have been associated with cutaneous melanoma tumorigenesis and progression including dysregulated DNA gene promoter region methylation, histone modification, and microRNA. Several of these major epigenetic aberrations have been developed into biomarkers. Epigenetic biomarkers can be detected in tissue and in blood as circulating DNA in melanoma patients. There is strong evidence that biomarkers in cutaneous melanoma will have an important role as companions to therapeutics and overall patient management. Important progress has been made in epigenetic melanoma biomarker development and verification of clinical utility, and this review discusses some of the key current developments and existing challenges. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据